Centrus Energy Corp vs Vaxcyte Inc. Common Stock — how do they compare? Centrus Energy Corp trades at $117.33 (market cap $2.75B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 3.8× Centrus Energy Corp's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 31 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| LEU | PCVX | |
|---|---|---|
Market Cap | $2.75B | $10.51B |
Volume | 573,041 | 2,644,694 |
Sector | Energy | Health |
52-Week High | $436.00 | $73.82 |
52-Week Low | $119.95 | $40.32 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.06B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with $448.70M revenue and $77.80M net income for 2025, though profitability declined in 2026. Recent multi-year HALEU supply contracts with Antares and Radiant highlight Centrus' strategic position in the nuclear fuel market as the only US-licensed HALEU producer.
The stock presents a compelling growth opportunity in nuclear energy infrastructure with 46% analyst buy ratings and $218.10 consensus price target, but faces execution risks amid high valuation multiples (P/E 71.05) and recent earnings volatility. Key risks include dependency on nuclear policy support and competitive pressures in uranium enrichment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →